NASDAQ: NKGen - “SNK01 autologous NK cell therapy demonstrated a positive effect on cerebral spinal fluid (“CSF”) and plasma Tau proteins in Alzheimer’s patients”
Confident in the NK tech, looking forward to phase 1 from ALA, outlook is positive.
Ann: Arovella Completes $12.5M Placement - Funded to Phase 1 Data, page-7
Add ALA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
16.0¢ |
Change
-0.005(3.03%) |
Mkt cap ! $168.2M | |||
| Open | High | Low | Value | Volume |
| 16.5¢ | 16.5¢ | 16.0¢ | $31.25K | 193.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 185049 | 16.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 16.5¢ | 405741 | 11 |
View Market Depth
| Last trade - 10.54am 10/10/2024 (20 minute delay) ? |
| ALA (ASX) Chart |